Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Merk

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
European Journal of Haematology|January 1, 1991
Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHLK Merk, K Ideström, B Johansson, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6E T Lennette, L Rymo, M Yadav, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1995
Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trialM Björkholm, U Axdorph, G Grimfors, et al.
Cancer|August 15, 1991
Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long-term follow-upO Tullgren, G Grimfors, G Holm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 1998
Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin's lymphomaF Celsing, S Widell, K Merk, et al.
Leukemia & Lymphoma|October 1, 1993
A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromesE Hellström-Lindberg, G Birgegård, M Carlsson, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1993
Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinomaJ P Wersäll, G Masucci, A L Hjelm, et al.
Leukemia & Lymphoma|July 29, 2016
A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic LeukemiaC Paul, U Tidefelt, G Gahrton, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
European Journal of Haematology|January 1, 1991
Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHLK Merk, K Ideström, B Johansson, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6E T Lennette, L Rymo, M Yadav, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 1995
Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trialM Björkholm, U Axdorph, G Grimfors, et al.
Cancer|August 15, 1991
Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. A long-term follow-upO Tullgren, G Grimfors, G Holm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 1998
Addition of etoposide to CHOP chemotherapy in untreated patients with high-grade non-Hodgkin's lymphomaF Celsing, S Widell, K Merk, et al.
Leukemia & Lymphoma|October 1, 1993
A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromesE Hellström-Lindberg, G Birgegård, M Carlsson, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1993
Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinomaJ P Wersäll, G Masucci, A L Hjelm, et al.
Leukemia & Lymphoma|July 29, 2016
A Randomized Comparison of Doxorubicin and Doxorubicin-DNA in the Treatment of Acute NonLymphoblastic LeukemiaC Paul, U Tidefelt, G Gahrton, et al.
Pageof 2